Blog
RSS FeedPosted by Michael Wonder on 30 Jan 2016
CADTH calls for patient input on a new submission from Celgene for Otezla
29 January 2016 - CADTH has received notice of a pending resubmission from Celgene for Otezla (apremilast) for use by patients ...
Posted by Michael Wonder on 21 Jan 2016
CADTH calls for patient input on two submissions from Novartis for Cosentyx
21 January 2016 - CADTH has received notice of pending submissions from Novartis for Cosentyx (secukinumab) for use by patients with ...
Posted by Michael Wonder on 18 Jan 2016
CADTH calls for patient input on a new submission from Celopharma for Mifegymiso
18 January 2016 - CADTH has received notice of a pending submission from Celopharma for Mifegymiso (mifepristone with misoprostol) for the ...
Posted by Michael Wonder on 16 Jan 2016
CADTH calls for patient input on a new submission from AstraZeneca for Brilinta
15 January 2016 - CADTH has received notice of a pending submission from AstraZeneca for ticagrelor (Brilinta) for the prevention of ...
Posted by Michael Wonder on 08 Jan 2016
CADTH publishes its final report on interventions for the management of symptomatic uterine fibroids
8 January 2016 - This systematic review addresses the effectiveness and safety of five uterine-preserving interventions available in Canada to alleviate ...
Posted by Michael Wonder on 07 Jan 2016
CADTH calls for patient input on submissions requesting advice on recent recommendations for new hepatitis C medicines
6 January 2016 - CADTH has received submissions requesting advice for Sovaldi, Harvoni, Holkira Pak & Daklinza. ...
Posted by Michael Wonder on 05 Jan 2016
Final CADTH reports on drugs for chronic hepatitis C infection
5 January 2016 - CADTH updated its previous therapeutic review examining the clinical and economic impact of new and existing drugs ...
Posted by Michael Wonder on 05 Jan 2016
CADTH calls for patient input on a submission from Gilead on new combination treatment for patients with HIV infection
4 January 2016 - CADTH has received the following notice of a pending submission from Gilead for emtricitabine with tenofovir ...
Posted by Michael Wonder on 04 Jan 2016
CADTH calls for patient input on a resubmission from BioMarin for Kuvan
4 January 2016 - CADTH has received notice of a pending submission from BioMarin for sapropterin dihydrochloride (Kuvan) for use by ...
Posted by Michael Wonder on 16 Dec 2015
CADTH calls for feedback: anti–vascular endothelial growth factor drugs for retinal conditions
16 December 2015 - A draft recommendation on the anti–vascular endothelial growth factor drugs for retinal conditions is now available for ...
Posted by Michael Wonder on 09 Dec 2015
CADTH releases report on cancer biomarker testing
9 December 2015 - The final environmental ccan report is now available for the CADTH project on cancer biomarker testing. ...
Posted by Michael Wonder on 07 Dec 2015
Updates to the Guidelines for the Economic Evaluation of Health Technologies: Canada
7 December 2015 - CADTH is updating the third edition of the Guidelines for the Economic Evaluation of Health Technologies: Canada. ...
Posted by Michael Wonder on 07 Dec 2015
CADTH calls for patient input on a new submission from Sanofi for Praluent
7 December 2015 - CADTH has received notice of a pending submission from Sanofi for Praluent (alirocumab) for use by patients ...
Posted by Michael Wonder on 01 Dec 2015
CADTH calls for patient input on a new submission from AstraZeneca for Xigduo
1 December 2015 - CADTH has received notice of a pending submission from AstraZeneca for Xigduo (dapagliflozin propanediol monohydrate with metformin ...
Posted by Michael Wonder on 20 Nov 2015
CADTH calls for patient input on a new submission from GSK for mepolizumab
20 November 2015 - CADTH has received notice of a pending submission from GSK for mepolizumab for use by patients with ...